La Jolla Pharmaceutical Co.
(NASDAQ : LJPC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 16.35%127.030.0%$2227.08m
BIIBBiogen, Inc. 0.84%243.781.7%$657.15m
AMGNAmgen, Inc. 2.04%224.811.3%$567.96m
GILDGilead Sciences, Inc. 0.89%60.031.0%$514.37m
NVAXNovavax, Inc. 22.51%125.6992.9%$508.55m
BNTXBioNTech SE 4.79%109.990.0%$483.37m
VRTXVertex Pharmaceuticals, Inc. 3.95%226.711.9%$475.11m
REGNRegeneron Pharmaceuticals, Inc. 1.13%514.052.7%$473.60m
ILMNIllumina, Inc. 4.29%317.033.5%$393.59m
APVOAptevo Therapeutics, Inc. 1.32%44.3918.3%$233.60m
SGENSeagen Inc. 2.22%169.125.8%$182.62m
EXASEXACT Sciences Corp. 2.00%118.1919.6%$179.47m
ALXNAlexion Pharmaceuticals, Inc. 0.73%123.832.0%$157.60m
HALOHalozyme Therapeutics, Inc. -2.21%40.2318.4%$131.67m
SRNESorrento Therapeutics, Inc. 18.12%8.151.4%$127.58m

Company Profile

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.